Research programme: Rpn13 inhibitors - Pi Therapeutics
Latest Information Update: 28 Sep 2016
At a glance
- Originator Johns Hopkins University
- Developer Pi Therapeutics
- Mechanism of Action ADRM1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cervical cancer; Head and neck cancer; Multiple myeloma